A Trial of MHB088C in Advanced Extrapulmonary Neuroendocrine Cancer

MHB088C for Injection, an antibody drug-conjugated molecule (ADC), is conjugated from a humanized monoclonal antibody targeting the B7-H3 molecule and a DNA topoisomerase I inhibitor (TOP1i) via protease-hydrolyzable linkers.The intervention will be administered intravenously at a dose of 2.0 mg/kg every 2 weeks (Q2W) until disease progression, withdrawal from the study, or death.